Rigel Pharmaceuticals, Inc. presented five key presentations at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain. One oral presentation and four poster presentations highlighted the efficacy and safety of REZLIDHIA® (olutasidenib) in patients with relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML). Dr. Jorge E. Cortes presented the five-year results from the Phase 2 pivotal cohort of the registrational trial, showcasing the durable responses and manageable safety profile of olutasidenib.
The oral presentation emphasized the significant impact of olutasidenib in patients with mIDH1 AML, including those who had previously received venetoclax. The data revealed complete remission rates, transfusion independence, and overall survival outcomes. Dr. Cortes highlighted the clinical benefits of olutasidenib, especially in patients who were refractory to prior venetoclax treatment.
The poster presentations delved into specific subgroups, such as elderly patients, those with mIDH1 AML secondary to myeloproliferative neoplasms (MPN), and patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). These presentations illustrated the efficacy and tolerability of olutasidenib in these populations, showcasing its potential as a bridge to transplant treatment and as a therapeutic option for patients with limited treatment choices.
Overall, the data presented at EHA 2024 support the strong efficacy and durability of response of REZLIDHIA in various mIDH1 AML patient populations. The findings highlight the therapeutic advancements offered by olutasidenib in addressing the unmet needs of patients with R/R mIDH1 AML. Rigel Pharmaceuticals remains committed to developing novel therapies that improve the lives of patients with hematologic disorders and cancer.
For more information on the studies and outcomes presented at the EHA 2024 Hybrid Congress, you can visit Rigel Pharmaceuticals’ website.
